Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sellers regret: coming tomorrow
Green Day to all!
josh have you ever considered another hobby? Model trains, fishing, golf, slot machines...the list is endless.
Slow incremental growth...
it is not what I guessed/professed the past week would be but I prefer it. Weds. may be different but a steady uptrend into Sept. in many ways is an ideal. I have no intention on trying to play the peaks and valleys on this one.
That to me is the million dollar question. Though I have no expectations of it, I am anxious to see if the PR gives us any hints of P3.
It is also the reason I refuse to take short term gains.
An even simpler deduction:
What kind of news to you actively release early?
Why would a CEO continue to add 1000 shares/day leading up to Weds. PR?
Positive writing is on the wall. The only variables left (for me) are how positive is the news and will we streamline to Phase 3?
Great Find Hal. Thanks.
FYI a lot of his numbers are very conservative (i.e. AD market = 5B). More like 15-20B...and rising.
I'm given you a hard time. Agreed. Let's call this the first toe hold to the ascent.
David you're right. I can't see and effective treatment and potential preventative for Alzheimer's getting any attention either. Looks like it's time to pull the big circus tent stake and move on.
As an investor, Don't under estimate the poster. You have data and the ceo in one place...the right place.
Bonjour Cbd.. Just bought in. This one is elementary math. Revenue should trump dilution. Safe double is what I see.
To the positives longs, have a great weekend!
20 some minutes left in last week of being an unknown.
I'm ready for our next and very green week.
Good luck.
Yep...and this is the OTC! The idea of i will get in at X and out at Y doesn't happen as often as much as folks talk about.
Respectfully, if you believe that this stock is a competitor in the CNS market... a nickel a share difference at this pps means almost nothing compared to the gains of the next 6 months.
And...there is plenty of room for competition in the uncharted waters of AD.
I will say it again, after our PR you will see Avxl being compared to ax*n for valuation. If we get 10% of that pps...Life changing for us and folks with CNS issues.
Ax*n up 20%+ on news that it is highly likely to work. I still think it is a scam.
Exciting times!
naysayers, please look at a basic 6 month chart. If we have good news we will likely continue up that path. Exceptional news, the fist building of a "cityscape" will form.
I wish more people had the "hardware" to risk investments in American companies for sake of GROWTH both personal and global.
Last chance to buy in the .40s. We will close @ .50...watch.
please do.
Josh, just click on "sell"...donezo. No more worries or stress.
I think this is attributed to the reference to retest at .45.
http://stocksntrade.com/anavex-life-sciences-corp-otcmktsavxl-getting-attention-of-experts-7464.html
I just added : )
Also lot of repost:
http://www.techsonian.com/blistering-penny-stocks-in-the-news-walter-energywltg-anavex-life-sciences-avxl-myson-groupmysn-bg-group-brgyy/12535657/
http://seekingalpha.com/article/3323515-premarket-biotech-digest-pfizer-in-china-anavex-alzheimers-focus
http://www.investorwired.com/active-morning-movers-roche-holding-ltd-rhhby-nestle-sa-nsrgy-sourcinglink-net-inc-snet-anavex-life-sciences-corp-avxl/1743800
Nice accumulation today! Looking good.
It will be interesting to see to see if the article gets any traction. AVXL is still very much an unknown and probably will be until Tues/Weds. Even then, biopharm OTCs seem to have a 48 hour delay effect.
We won't see real gains until next week.
I think we'll see .62-.65 by Friday.
Then .85 by Tuesday.
I expect Missling to have a 2nd PR shortly after Weds. (like Monday) that addressing a P2 streamline.
Sounds like will be a positive write-up.
"Smart money sells on news"?
Maybe...but I think we will see dumb, silly money post PR.
Poster.
Which, a couple years ago I use to roll my eyes at but it turns out that these are taken seriously/formally. Posters are where lucrative investment opportunities lie (i.e. with the key note speaker...it's probably too late). There is opportunity for one-on-ones, questions, etc.
That's correct. PR on the 22nd. Confirmed with Christine w/ IR a few days back.
thanks. great post.
Patent application
Anavex has filed a patent application for the ANAVEX PLUS combination of donepezil (Aricept®) and ANAVEX 2-73. If granted, patent protection for ANAVEX PLUS will be in place until at least 2033.
http://www.anavex.com/pipeline/anavex-plus/
Scott, can you provide a link confirming that?
thanks.
RE: the 2-73 patent
Yes, it would indeed be amazing to have "issuance" delivered this week. Missling would enter my ceo hall of fame. This really is a trust in management issue. I am wondering if the "Plus" aspect is the hold-up.
Let's say A-273 is a rock-star drug with no IP...even in the worse case scenario with a licensing battle/IP infringement/bigs checks issued/the works..AVXL is still grossly undervalued!
AND...a patented 3-71 is in the chamber.
correction (thanks bernardc)
2500% not 1300%
a flame for lost moths.
With their valuation...AVXL would have a market cap ~11.7B.
{$50/ps X 235M (outstanding shares) = 11.7B}
This supports my earlier point, the more speculative valuations about an AD drug hitting the market...the more OBVIOUSLY undervalued AVXL is.
Perspective: If you bought AVXL today and we achieve a modest 1B market cap in the coming months....that's 1300% on your investment.
Thanks.
Absolutely right: 1.6B v. 40M
And a comp pps of 18$ is bad why??
Drano, start shaking you head up and down rather than side to side...AXON will serve as a comp for others determining valuation of AVXL in the coming weeks.